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Summary
 
Jaw1 is an endoplasmic reticulum (ER) resident protein representative of a class of proteins post
translationally inserted into membranes via a type II membrane anchor (cytosolic NH
 
2
 
 domain,
lumenal COOH domain) in a translocon-independent manner. We found that Jaw1 can effi-
ciently deliver a COOH-terminal antigenic peptide to class I molecules in transporter associ-
ated with antigen processing (TAP)-deficient cells or cells in which TAP is inactivated by the
ICP47 protein. Peptide delivery mediated by Jaw1 to class I molecules was equal or better than
that mediated by the adenovirus E3/19K glycoprotein signal sequence, and was sufficient to
enable cytofluorographic detection of newly recruited thermostabile class I molecules at the
surface of TAP-deficient cells. Deletion of the transmembrane region retargeted Jaw1 from the
ER to the cytosol, and severely, although incompletely, abrogated its TAP-independent pep-
tide carrier activity. Use of different protease inhibitors revealed the involvement of a nonpro-
teasomal protease in the TAP-independent activity of cytosolic Jaw1. These findings demon-
strate two novel TAP-independent routes of antigen processing; one based on highly efficient
peptide liberation from the COOH terminus of membrane proteins in the ER, the other on
delivery of a cytosolic protein to the ER by an unknown route.
ˇ c
 
M
 
HC class I molecules bind peptides of 8–10 residues
derived from intracellular proteolytic degradation
and present them at the cell surface to CD8
 
1
 
 T lympho-
cytes (T
 
CD8
 
1
 
) (1, 2). In the absence of high affinity peptide
ligands, cell surface class I molecules are unstable at 37
 
8
 
C
and rapidly denature (3). Such denaturation can often be
detected by mAbs specific for the 
 
a
 
1
 
a
 
2 domains: the bind-
ing of such mAbs to live cells provides a measure of the ca-
pacity of cells to produce class I molecules with stable pep-
tide ligands.
The generation of the majority of class I–associated pep-
tides involves cytosolic proteolysis. Little is known about
how proteins are targeted in the cytosol for the production
of class I–binding peptides. The nature of the proteases in-
volved is only slightly better defined. The proteasome, an
abundant, heterogeneous, macromolecular multicatalytic
protease, has been implicated in the generation of a sub-
stantial portion of class I–binding peptides (4, 5). Other cy-
tosolic proteases might also contribute to peptide genera-
tion, because proteasome inhibitors only partially block
class I assembly and antigen presentation (6–9). Peptides of
8–16 or so residues produced by cytosolic proteolysis are
transported into the endoplasmic reticulum (ER)
 
1
 
 by the
transporters associated with antigen processing (TAP), the
MHC-encoded member of the ATP binding cassette trans-
porter family of proteins (10–13). Longer peptides may also
be transported, but at much reduced efficiency (14).
Functional TAP is required for the optimal assembly of
class I molecules, as shown by the poor cell surface expres-
sion of class I molecules by TAP-deficient cells (15–18).
This is due to absence of peptides in the ER, because deliv-
ery of peptides to the ER by appendage of a hydrophobic
signal sequence can restore surface expression of class I
molecules (19–22). Such peptides are thought to enter the
ER by transiting the translocon, where signal peptidase lib-
 
1
 
Abbreviations used in this paper:
 
 BFA, brefeldin A; ER, endoplasmic reticu-
lum; FBS, fetal bovine serum; MOI, multiplicity of infection; NP, nucle-
oprotein; rVV, recombinant vaccinia virus; TAP, transporter associated
with antigen processing; VV, vaccinia virus.
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erates the class I–binding peptide from the hydrophobic
signal sequence.
The ability of TAP to transport peptides longer than
those usually recovered from class I molecules raises the
possibility of peptide trimming in the ER, with peptide ei-
ther free or bound to class I as originally proposed (23). Using
TAP-deficient cells, it has been shown that class I–binding
peptides can be liberated from longer precursors targeted to
the ER via the translocon (24, 25). Peptide liberation oc-
curs most readily from short precursors, but under some
circumstances, class I–binding peptides can be derived from
full-length proteins (26).
In the present study, we explore the capacity of ER-
associated proteases to process antigenic peptides from the
lumenal domain of Jaw1. Jaw1 is an ER resident protein
whose known expression is limited to cells of hematopoi-
etic origin (27). Jaw1 lacks a NH
 
2
 
-terminal signal sequence,
and is inserted into the membrane posttranslationally by a
hydrophobic transmembrane region at residues 480–503
(28). Jaw1 consists of a large cytosolic domain of several
coiled coils, the aforementioned transmembrane region,
and a 35-residue lumenal tail (see Fig. 1). The membrane
topology of Jaw1 and posttranslational insertion into the
ER are representative of a number of integral membrane
proteins (29). The membrane insertion of these proteins
appears to occur independently of the translocon. In the
course of investigating the antigen processing of a form of
Jaw1 lacking the membrane anchor/insertion sequence, we
unexpectedly encountered a novel route of delivery of an-
tigenic peptides to class I molecules whose generation is
dependent on a nonproteasomal activity.
 
Materials and Methods
 
Biochemical Procedures.
 
T2 or L929 cells (2 
 
3
 
 10
 
6
 
) were in-
fected with recombinant vaccinia virus (rVV) for 3 h at 37
 
8
 
C, in-
cubated for 30 min in 5 ml methionine-free DMEM (Biofluids,
Rockville, MD) to deplete intracellular methionine pools. In-
fected cells were labeled with 50 
 
m
 
Ci [
 
35
 
S] methionine (Amer-
sham, Arlington Heights, IL) in 200 
 
m
 
l methionine-free DMEM
for 5 min. After washing in PBS containing 2 mg/ml free me-
thionine (PBS/Met), cells were chased in IMDM for the indi-
cated times. Cells were pelletted by centrifugation and suspended
in lysis buffer (0.15 M NaCl, 1 mM EDTA, 1% Triton X-100, 10
mM Tris–HCl, pH 7.4, Complete
 
Ô
 
 protease inhibitor cocktail)
(Boehringer Mannheim, Indianapolis, IN). Where indicated, cells
were pretreated and proteasome inhibitors added at the concentra-
tions described above. Lysates were collected with affinity-puri-
fied rabbit anti-Jaw polyclonal antibodies (28) conjugated to protein
A–Sepharose (Pierce, Rockford, IL) for 2 h at 4
 
8
 
C with constant
rotation. Beads were washed extensively and boiled in sample
buffer containing 0.125 M Tris–HCl, pH 6.8, 4% SDS, 20%
glycerol, 10% 2-mercaptoethanol. Samples were analyzed by
SDS-PAGE according to Laemmli (30). Gels were dried by vac-
uum and exposed to phosphorescent screens overnight and for 1 wk.
Screens were imaged using a Phosphor Imager (Molecular Dy-
namics, Sunnyvale, CA). Images were prepared using Adobe
Photoshop and printed with a Fujix Pictrography digital printer
(Fuji Medical Systems, Stamford, CT).
 
Cell Lines.
 
L929 cells (American Type Culture Collection,
Rockville, MD) and L929 transfected with genes coding for the
MHC molecules K
 
b
 
 (L-K
 
b
 
) or D
 
b
 
 (L-D
 
b
 
 cells) were maintained in
DMEM supplemented with 7.5% FBS. T2 cells (16) and their
class I transfectants T2-K
 
k
 
, T2-D
 
b
 
 were maintained in IMDM
supplemented with 7.5% fetal bovine serum (FBS) (vol/vol). T2-K
 
d
 
cells were maintained in RPMI-1640 supplemented with 7.5%
FBS. All cell lines were incubated at 37
 
8
 
C, 91% Air, 9% CO
 
2
 
.
 
Cytofluorography.
 
T2-K
 
d
 
 cells were infected with rVV at 10
PFU/cell for 16 h at 37
 
8
 
C with gentle rotation. Cells were washed
in ice-cold PBS containing 1% rabbit serum, and incubated with
SF1.1.1 mAb conjugated to FITC (PharMingen, San Diego, CA)
at a 1:10 dilution for 30 min at 0
 
8
 
C, washed extensively in ice-
cold PBS, and analyzed with a FACScan
 
Ò
 
 (Becton Dickinson,
San Jose, CA). Cells were suspended in ethidium homodimer
(Molecular Probes, Eugene, OR) (10 
 
m
 
g/ml), and analysis was
restricted to viable cells (nonfluorescent in FL3 photomultiplier
tube).
 
Electron Microscopy.
 
T2 cells were infected with rVVs for 6 h.
Cells were washed twice in PBS and fixed in 0.5% glutaraldehyde
for 15 min at room temperature. Cells were washed twice in PBS
and fixed in a mixture of 3% paraformaldehyde and 0.5% glutaral-
dehyde in PBS for 15 min at room temperature. The cells were
washed in PBS and further processed for cryomicrotomy and im-
munolabeling essentially according to methods described by
Tokuyashu (31). Frozen–thawed sections were indirectly labeled
with a 1:500 dilution of rabbit anti-Jaw antiserum followed by
10-nm colloidal gold coated with protein A (Aurion, Wagenin-
gen, Netherlands). The ultrathin sections were examined with a
Philips EM400 electron microscope.
 
Protease Inhibitors.
 
cbz–LL–CHO, cbz–LLL–CHO, and cbz–
LLF–CHO were synthesized as described (32). Lactacystin was
purchased from E.C. Corey (Harvard University, Cambridge,
MA). N–Ac–LLnL and N–Ac–LLnM were purchased from Cal-
biochem Novabiochem (La Jolla, CA). Other inhibitors were
purchased from Sigma Chemical Co. (St. Louis, MO).
 
Mice.
 
6–8-wk-old BALB/cByJ, CBA/J, and C57BL/6J mice
were purchased either from the Jackson Laboratories (Bar Harbor,
ME) or Taconic Farms (Germantown, NY). Mice were primed
intravenously with rVVs (5 
 
3
 
 10
 
6
 
 PFU) or intraperitoneally with
PR8 (200HAU) in BSS/BSA and spleens taken at least 3 wk after
priming.
 
Microcytoxicity Assays.
 
Target cells (2 
 
3
 
 10
 
6
 
) were infected
with rVV (2 
 
3
 
 10
 
7
 
 PFU) for 1 h in balanced salt solution, 0.2%
BSA (BSS/BSA), followed by an additional 3-h incubation in
IMDM. Cells were labeled with 20 
 
m
 
l IMDM with 10 
 
m
 
Ci
Na
 
51
 
CrO
 
4
 
 (Amersham, Arlington Heights, IL) for 1 h at 37
 
8
 
C
and washed in IMDM. Target cells were suspended in IMDM
and incubated with splenic effector cells for 6 h at 37
 
8
 
C. Effector
cells were generated from splenocytes primed with rVV express-
ing full-length protein antigen or minigenes and stimulated in
vitro by PR8-infected autologous spleen cells. Where indicated,
brefeldin A (BFA) (Sigma Chemical Co.) was added to cells at
5 
 
m
 
g/ml and maintained throughout the remaining incubations.
In experiments with peptidyl aldehyde inhibitors, target cells
were pretreated with either 25 
 
m
 
M inhibitor or as indicated in
the Fig. 6 legend for 30 min at 37
 
8
 
C. Inhibitors were present dur-
ing the 4-h infection.
 
Peptide Extraction.
 
Peptides were extracted in trifluoroacetic
acid as previously described (24) with minor modifications. T2
cells (10
 
9
 
) were coinfected with rVV expressing K
 
d
 
 or EC15K
 
d
 
and rVV-expressing Jaw1 constructs at multiplicity of infection
(MOI) of 10 for 1 h at 37
 
8
 
C. Cells were incubated at 37
 
8
 
C for an 
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additional 16 h in 100 ml IMDM. Cell pellets were lysed in 10 ml
0.1% trifluoroacetic acid, Dounce homogenized, and sonicated.
Lysates were passed through Macrosep filters (Filtron Technology
Corp., Northborough, MA) to collect material 
 
,
 
3,000 kD. Fil-
trates were vacuum concentrated and resuspended in 500 
 
m
 
l PBS.
Serial twofold dilutions were incubated with 
 
51
 
Cr-labeled P815
cells in 50 
 
m
 
l for 2 h at 26
 
8
 
C. To maximize binding of exogenous
peptides, P815 cells were cultured overnight at 26
 
8
 
C with 5 
 
m
 
g/
ml human 
 
b
 
2
 
-microglobulin (Sigma). Nucleoprotein (NP)-spe-
cific effector cells were added at 10:1 effector to target ratio and
incubated an additional 6 h. Percent-specific lysis was calculated
as described above.
 
Viruses.
 
The influenza virus A/PR8/(H1N1) (PR8) was grown
in 10-d-old embryonated chicken eggs and used as infectious al-
lantoic fluid. Recombinant VV were grown in thymidine kinase mi-
nus (TK
 
2
 
) human 143B osteosarcoma cells. rVV expressing NP,
SNP, cytosolic and ER-targeted peptides have been described
(20, 33). VV–ICP47 (34) and VV–Kex2 (35) were provided by
B. Rouse (University of Tennessee, Knoxville, TN) and D. Thomas
(University of Oregon, Eugene, OR), respectively. Jaw1[NP
 
147–155
 
]
and Jaw1 (Lum
 
2
 
)[NP
 
147–155
 
] were engineered by PCR of the full-
length Jaw1 mouse cDNA using the 5
 
9
 
 primer CTATTA-
GGTGACACTATAGAACAGACACCATGGCTCTCTGTG-
TAAAAGGT-CCC with unique 3
 
9
 
 primers GGGGTACCT-
CATCACACTAGTGCTCGTGTTCGCTGGTATGTAGCC-
TCCACGGCTGTCTG (Jaw1(Lum
 
2
 
)[NP
 
147–155
 
] and GGGTAC-
CTCATCAC-CTAGTGCTCGTGTTCGCTGGTATGTTCG-
TTTCGTCGCACTGGCGGTGGTCCATC (Jaw1[NP
 
147–155
 
]).
The constructs contain a 
 
b
 
-globin leader sequence upstream of the
initiator ATG of Jaw1. Jaw1(Lum
 
2
 
) [NP
 
147–155
 
] has the NP
 
147–155
 
peptide TYQRTRALV fused in-frame after amino acid Ala509
and is followed by two stop codons. Jaw1[NP
 
147–155
 
] has the
Kex2/furin protease site RRKR and the peptide TYQRTRALV
fused in-frame following the penultimate Val539 of the Jaw1
cDNA. Both PCR fragments were cloned blunt-ended into the
SmaI site of pSP72 (Promega), digested with SalI and KpnI, and
then subcloned into pSC11. Jaw1(TM
 
2
 
)[NP
 
147–155
 
] was engi-
neered by first amplifying the COOH-terminal half of the Jaw1
cDNA using an internal primer 5
 
9
 
 GGGCTGGTGTCAG-
GCATG and a 3
 
9
 
 primer GGGGTACCTCATCACACT-
AGTGCTCGTGTTCGCTGGTATGTGACCCAGGAAGCCA-
CTGA, which placed NP
 
147–155
 
 in-frame with Jaw1 following
amino acid Val467 (upstream of the transmembrane domain).
This fragment was digested with NaeI and KpnI and then sub-
cloned into the same sites of the Jaw1(Lum
 
2
 
)[NP
 
147–155
 
] plasmid,
replacing the COOH-terminal coding region of that plasmid.
The [NP
 
147–155
 
]Jaw1 construct used the following primers in
PCR of the Jaw1 cDNA: 5
 
9
 
-GATCGTCGACAAACA-
GACACCATGACATACCAGCGAACACGAGCACTAGTGC-
TCTGTGTAAAAGGTCCC and 3
 
9
 
-CATTGAGCTGCAC-
GTCAGTCA. This construct fuses the immunogenic peptide in
frame immediately following the initiator ATG of full-length
Jaw1. The PCR fragment was digested with SalI and BamHI and
cloned into pSP72 before shuttling into pSC11 and pSC65. All
constructs were sequenced to ensure fidelity of PCR.
 
Results
 
Characterization of Jaw1-expressing rVVs.
 
To study the abil-
ity of Jaw1 to deliver an antigenic peptide to the ER, we pro-
duced rVVs encoding the NP
 
147–155
 
 peptide at the COOH
terminus of either intact Jaw1 (Jaw[NP
 
147–155
 
]), or truncated
versions lacking the lumenal domain (Jaw1(Lum
 
2
 
)[NP
 
147–155
 
]),
or both the lumenal and transmembrane domains (Jaw1
(TM
 
2
 
)[NP
 
147–155
 
]). In designing Jaw1[NP
 
147–155
 
] we in-
serted an additional tetrapeptide sequence at the peptide–
Jaw1 interface that enables cleavage by the yeast Kex2 pro-
tease. We also produced a rVV-expressing Jaw1 with the
NP
 
147–155
 
 peptide appended to the NH
 
2
 
 terminus ([NP147–155]
Jaw1) that serves as a topological control for the COOH-
terminal NP147–155-expressing chimeras. The various Jaw1
chimeric molecules are depicted schematically in Fig. 1 A.
Jaw1-containing gene products were initially character-
ized by SDS-PAGE of material collected with polyclonal
rabbit anti-Jaw1 antibodies from [35S]methionine-labeled
detergent extracts prepared from rVV-infected cells (Fig. 1
B). Cells were radiolabeled for 5 min at 378C and chased
for up to 3 h at this temperature. In previous studies, we
observed that Jaw1 migrates in SDS-PAGE with apparent
mobility 10 kD greater than predicted (27). VV-encoded
Jaw1 similarly migrates more slowly than predicted. This
may be due to posttranslational modifications, but any such
modifications would have to be rapid and complete be-
cause pulse-labeled material migrated as a single species.
Therefore, it is more likely that the protein migrates aber-
rantly in SDS-PAGE. None of the Jaw1 chimeric proteins
are N-glycosylated as determined by unaltered mobility af-
ter endoglycosidase H digestion (data not shown).
As anticipated, Jaw1 (TM2)[NP147–155] migrated most
rapidly, followed by Jaw1(Lum2)[NP147–155]. Neither of
these proteins was detectably modified over the 3-h chase
Figure 1. (A) Schematic representation of rVV expressed Jaw1 chi-
meric proteins. (B) Biochemical characterization of Jaw1 chimeric pro-
teins. Species reactive with anti-Jaw1 antisera present in detergent extracts
of rVV-infected cells pulse radiolabeled and chased for the indicated time
in hours were analyzed by SDS-PAGE and visualized using a Phosphor-
Imager. Only the region containing the antibody-reactive species is
shown. The far left lane contains molecular weight markers indicated.
The asterisk identifies a proteolytic fragment created by the action of
Kex2 on Jaw1[NP147–155].1090 Production of TAP-independent Peptides
period. Jaw1[NP147–155] migrated with an apparent molecu-
lar mass of 4 kD greater than Jaw1(Lum2)[NP147–155],
which is consistent with the addition of a 42-residue lume-
nal domain. [NP147–155]Jaw1 migrated 3 kD more slowly
than Jaw1(Lum2)[NP147–155]. Sequencing of the 59 and 39
ends of all of the genes revealed the expected sequences, so
we again attribute the different mobilities to nonclassical
SDS-PAGE behavior. During the chase period, [NP147–155]
Jaw1 and Jaw1[NP147–155] were converted into more rap-
idly migrating forms. We previously showed this was likely
due to proteolysis of the COOH terminus (28). By con-
trast, Jaw1(Lum2)[NP147–155] and Jaw1(TM2)[NP147–155]
were not detectably cleaved over the 3-h chase period.
This confirms the absence of lumenal domains in these
proteins. The function of the Kex2 protease site was con-
firmed by coinfection of cells with VV–Jaw1[NP147–155] and
a rVV that directs the synthesis of Kex2, a secretory protease
expressed at limiting levels by most cells (35). This resulted
in the presence of a novel species migrating slightly faster than
the pulse-labeled material (designated by an asterisk in Fig.
1 B), consistent with the removal of a small terminal peptide.
The intracellular targeting of two of the recombinant Jaw1
constructs was examined by cryoimmuno electron micros-
copy using colloidal gold-conjugated secondary antibodies to
detect binding of anti-Jaw1 antibodies (Fig. 2). Almost all
Jaw1(Lum2)[NP147–155] detected was associated with intra-
cellular membranes, whereas Jaw1(TM2)[NP147–155] local-
ized to the cytosol and was not specifically associated with
membranes. Immunofluorescence of fixed and permeabi-
lized cells with the anti-Jaw1 antiserum confirmed the ex-
pected location of each of the four Jaw1-chimeric proteins
(data not shown).
Figure 2. Immunogold local-
ization of Jaw1 proteins. Jaw1
was located in rVV-infected T2
cells by cryoimmunogold label-
ing. (A) Cells expressing Jaw1
(Lum2)[NP147–155]. Gold parti-
cles specifically decorate the nu-
clear membrane and cytoplasmic
membrane structures. (B) Cells
expressing Jaw1 (TM2)[NP147–155].
Gold particles are located in the
cytosol. In addition to the differ-
ence in patterns between A and
B, the specificity of Jaw staining
was shown by the absence of
gold particles on sections pre-
pared from cells infected with a
control rVV.1091 Snyder et al.
Liberation of NP147–155 from Jaw 1 Constructs: Antigen Pre-
sentation. The antigen processing of Jaw1 constructs was
studied in T2 cells (a TAP-deficient human lymphoid cell
line) or L929 cells (a TAP-expressing mouse cell line). To
enable recognition by Kd-restricted, NP-specific TCD81,
cells were coinfected with a rVV expressing Kd in addition
to the Jaw1-expressing rVV. As seen in Fig. 3, L929 cells
presented NP147–155 from the COOH termini of both
Jaw1(Lum2)[NP147–155] and Jaw1(TM2)[NP147–155]. Pre-
sentation from the NH2 terminus of Jaw1 occurred at
much lower levels. Because a Met-initiated cytosolic mini-
gene product that is identical to the 10 NH4-terminal resi-
dues of [NP147–155]Jaw1 is effectively presented by L929
cells (designated in Fig. 3 and [NP147–155]), this indicates
that the Jaw1-derived COOH-terminal flanking sequences
cannot be efficiently removed from NP147–155 by cytosolic
proteases. This compromises the use of this construct as a
control in T2 cells, but only partially, because the activities
of cytosolic proteases and secretory proteases are expected
to be independent.
In T2 cells, both Jaw1(Lum2)[NP147–155] (Fig. 3) and
Jaw1[NP147–155] (data not shown) were efficiently presented
after short VV infections (,4 h). This cannot be attributed
to leakiness of the cells for cytosolic peptides, because un-
der the same conditions, the cytosolic minigene, that is
produced in enormous amounts relative to the amount of
peptide liberated in the cytosol from proteins (36), was not
presented above background values obtained with a control
VV. [NP147–155]Jaw1-infected cells were recognized by
NP-specific TCD81 at levels observed using cells infected
with control rVVs. This is consistent with the predicted to-
pology of Jaw1, but we cannot eliminate the possibility that
the secretory pathway, like the cytosol, is incapable of lib-
erating the NP147–155 peptide from the NH2 terminus of
Jaw1. NP147–155 was liberated from Jaw1(TM2)[NP147–155],
but at far lower efficiency than from the transmembrane
domain containing molecules (see Figs. 4 and 5).
Liberation of NP147–155 from Jaw1-constructs: cytofluorogra-
phy. We recently found that after infection of T2-Kd cells
with rVVs encoding ER-targeted class I–binding peptides,
enhanced Kd cell surface expression can be cytofluoro-
graphically detected after staining with Kd-specific mAbs
(37). This provides a much more quantitative measure of
the efficiency of antigen presentation than TCD81-mediated
lysis. As previously observed, infection with a rVV express-
ing ER-targeted NP147–155 resulted in a clear increase in the
amount of mAb-reactive cell surface Kd on the surface of
T2-Kd cells (Fig. 4). Remarkably, the greatest increase in
Figure 3. Presentation of NP147–155 by rVV-infected cells. rVV-infected cells expressing the Jaw chimeric proteins were tested for lysis by NP-specific
secondary TCD81 at the indicated effector to target ratio. Cells were coinfected with a rVV expressing Kd to enable recognition.
Figure 4. Rescue of Kd cell surface expression. T2-Kd cells were in-
fected with the rVV indicated and the amount of cell surface Kd present
on viable cells cytofluorographically determined using a directly conju-
gated Kd-specific mAb. Data are expressed as mean channel fluorescence
3 100. The last three bars on the right represent cells coinfected with
Jaw1[NP147–155] and the rVV indicated (ACE, angiotensin-converting en-
zyme).1092 Production of TAP-independent Peptides
Kd expression was observed after infection with VV–Jaw1
(Lum2)[NP147–155]. Kd was rescued slightly less efficiently
by expression of Jaw1[NP147–155]. These effects can be at-
tributed to the presence of the NP147–155 peptide at the
COOH terminus of Jaw1, because expression of [NP147–155]
Jaw1 had no effect on Kd expression. Thus, peptides gener-
ated from Jaw1 sequences do not themselves bind Kd and
rescue expression. These findings demonstrate that Jaw1 ef-
ficiently delivers peptides to the class I processing pathway.
In contrast with membrane-targeted Jaw1, expression of
Jaw1(TM2)[NP147–155] had no effect on Kd expression. This
demonstrates the importance of proper insertion of Jaw1
[NP147–155] into the membrane to enable efficient peptide
liberation in the secretory pathway.
In this experiment, we also examined whether liberation
of NP147–155 from Jaw1[NP147–155] could be enhanced by
coexpression of the yeast Kex2 protease encoded by a rVV.
Because this entails coinfection with two rVVs, it was nec-
essary to control for competition between rVVs for gene ex-
pression. Coinfection with VV reduced the Jaw1[NP147–155]-
mediated rescue of Kd expression. Above this baseline value,
Kex2 coexpression clearly increased Kd rescue, whereas a
rVV expressing the secretory carboxypeptidase angiotensin-
converting enzyme had little effect on Kd expression, dem-
onstrating the specificity of Kex2-mediated enhancement.
These findings indicate that it is possible to modify the antigen
processing of Jaw1 by coexpressing a protease.
NP147–155 Liberated from Jaw1 Binds Kd in the ER of T2
Cells. To examine the site of liberation of NP147–155 from
Jaw1, we extracted peptides from cells coinfected with the
Jaw1 expression rVVs and VV–EC15Kd. EC15Kd is a mod-
ified Kd molecule retained in the early secretory pathway
by replacement of the normal cytosolic domain with that of
E3/19K (38). The low relative molecular mass peptides
present in trifluoroacetic acid homogenates prepared from
infected cells were used to sensitize P815 cells for lysis by
NP-specific TCD81. As seen in Fig. 5, antigenic peptides
were recovered from cells expressing either Jaw1(Lum2)
[NP147–155] or Jaw1(TM2)[NP147]. At least eightfold greater
quantities of peptide were recovered from Jaw1(Lum2)
[NP147–155] expressing cells than from Jaw1 (TM2)[NP147–155]-
expressing cells. In an additional experiment in which we
reached an endpoint with all of the lysates, we recovered
z40-fold more NP147–155 activity from cells expressing
Jaw1(Lum2)[NP147–155] than those expressing Jaw1(TM2)
[NP147–155]. These findings are consistent with data in Fig.
4, in demonstrating that ER-targeted Jaw1 is a much more
efficient vehicle for TAP-independent loading of Kd mole-
cules with NP147–155 than cytosolic Jaw1. Peptide recovery
from Jaw1(TM2)[NP147]-expressing cells absolutely required
coexpression of EC15Kd, whereas recovery from cells ex-
pressing Jaw1(Lum2)[NP147–155] was largely, but not en-
tirely dependent on the EC15Kd expression (,5% of pep-
tides were recovered in a Kd-independent manner). This
small Kd-independent population of peptides may derive
from endogenously expressed human class I molecules by
T2 cells that weakly bind the peptides. Alternatively, the
peptide (or a precursor that can be processed by cell surface
of serum proteases in the course of sensitizing target cells),
may be produced/stabilized in a class I–independent manner
in the secretory pathway. To demonstrate that peptide as-
sociation with Kd occurred before lysis of the cells, cells ex-
pressing VV–EC15Kd were mixed with VV–Jaw1(Lum2)
[NP147–155]-infected cells and then lysed (Fig. 5, Cell Mix).
This resulted in only a slight increase in the amount of pep-
tide present in the extracts relative to VV–Jaw1(Lum2)
[NP147–155]-infected cell lysates, demonstrating that the vast
majority of NP147–155 liberated from Jaw1(Lum2)[NP147–155]
associates with Kd intracellularly. Based on these findings,
we conclude that NP147–155 is produced from both Jaw1(TM2)
[NP147–155] and Jaw1 (Lum2)[NP147–155] in the early secre-
tory pathway of T2 cells, probably the ER itself.
NP147–155 Is Liberated from Jaw1(TM2)[NP147–155] by a
Novel Protease Activity. The unexpected presentation of
NP147–155 from Jaw1(TM2)[NP147] in T2 cells hinted at an
unusual mechanism of peptide entry into the class I presen-
tation pathway. The cellular localization of Jaw1(TM2)/
NP147–155 suggested cytosolic proteases may participate in
liberating NP peptide from Jaw1(TM2). Peptide aldehyde
inhibitors have been used to characterize protease activities
that contribute to the production of class I–binding pep-
tides. We initially studied the effect of the peptide aldehyde
inhibitor cbz–LLL–CHO on the liberation of NP147–155
from different precursors in T2 cells. cbz–LLL–CHO
blocks all of the known activities of 20S proteasomes in
vitro, and causes the accumulation of the ubiquitinated
proteins in vivo (4, 32). T2 cells were treated with cbz–
LLL–CHO before infection and throughout the 4-h incu-
bation period before the 51Cr release assay. At this time,
cbz–LLL–CHO was replaced with BFA to prevent further
Figure 5. Quantitation of acid-soluble peptides in cell extracts. Extracts
prepared from cells expressing ER retained Kd (Kd Ret) and the indicated
Jaw1 chimeric protein were tested for their ability to sensitize P815 cells
for lysis by NP-specific TCD81. Cell mix refers to a sample in which ER-
retained Kd expressing cells were mixed with Jaw1(Lum2)[NP147–155]-
expressing cells before lysis.1093 Snyder et al.
delivery of class I–peptide complexes produced after the re-
moval of cbz–LLL–CHO.
Using cbz–LLL–CHO at concentrations 12.5 or 25 mM
did not detectably affect the liberation of NP147–155 from
Jaw1(Lum2)[NP147–155] (Fig. 6). By contrast, recognition of
Jaw1(TM2)[NP147] expressing cells was dramatically re-
duced by cbz–LLL–CHO at either concentration. The ef-
fects of cbz–LLL–CHO cannot be attributed to blocking
viral gene expression as demonstrated by cytofluorographic
analysis of cells infected with a rVV-expressing mouse
Figure 6. Effect of protease inhibitors on generation of the NP147–155 peptide. rVV-infected T2-Kd cells expressing the indicated protein were incu-
bated with the indicated protease inhibitor starting 30 min before infection and ending 4 h after infection. BFA was then added to cells to prevent addi-
tional antigen presentation and cells were incubated with NP147–155-specific TCD81 in a standard microcytotoxicity assay at the effector to target ratios in-
dicated. Inhibitors were used at the following concentrations: NH4Cl, 25 mM; cbz–LL–CH, 12.5 mM; cbz–LLL–CHO 12.5 mM (A and B), 25 mM (C);
lactacystin. 10 mM; N–Ac–LLnL, 200 mM; N–Ac–LLnM, 200 mM. The three panels are derived from separate experiments.1094 Production of TAP-independent Peptides
ICAM 1. Cell surface levels of ICAM detected with satu-
rating amounts of a directly conjugated mAb were not al-
tered by cbz–LLL–CHO under the conditions used for
studying antigen presentation (data not shown).
In addition to its effects on proteasomes, cbz–LLL–CHO
inhibits other cytosolic and lysosomal proteases. To deter-
mine the nature of the target protease, we examined the ef-
fects of five additional protease inhibitors on the liberation
of NP147–155 in T2 cells (Fig. 6). None of the inhibitors
blocked presentation of NP147–155 by Jaw1(Lum2)[NP147–155]-
expressing cells, indicating that global effects antigen presenta-
tion or viral gene expression are minimal and, therefore,
that any effects on presentation of Jaw1(TM2)[NP147]-
expressing  cells are due to specific blockade of determinant
liberation. Two of the additional inhibitors tested, cbz–LLF–
CHO (data not shown) and cbz–LL–CHO blocked the lib-
eration of NP147–155 from Jaw1(TM2)[NP147]. cbz–LLF–
CHO inhibits both proteasomes and other cellular proteases,
whereas cbz–LL–CHO does not detectably affect protea-
some activity at the concentration used (39), suggesting
that the effects of peptide aldehyde inhibitors on presenta-
tion of Jaw1(TM2)[NP147] are due to blockade of nonpro-
teasomal proteases. This was confirmed by the failure of
lactacystin to affect presentation of Jaw1(TM2)[NP147].
Lactacystin is the most specific proteasome inhibitor that
acts by covalently binding to an enzymatic subunit (40).
Like cbz–LLF–CHO, it predominantly blocks the chymo-
tryptic-like, and tryptic-like activities of proteasomes.
It was recently reported that processing of signal peptides
in the ER of T2 cells was inhibited by 250 mM N–Ac–LLnL
(6). Presentation of Jaw1(TM2)[NP147] was not signifi-
cantly inhibited by N–Ac–LLnL (or N–Ac–LLnM) at con-
centrations of 200 mM (Fig. 6) or 300 mM (data not
shown), demonstrating that this protease activity is not re-
quired for processing of Jaw1(TM2)[NP147]. Presentation
was also unaffected by NH4Cl (Fig. 6) or leupeptin (data
not shown) indicating that endosomal proteases unlikely to
be involved in processing. The sensitivity of Jaw1(TM2)/
NP147–155 to protease inhibitors demonstrates that it and
Jaw1(Lum2)[NP147–155] are processed in a fundamentally
different manner by TAP-deficient cells.
TAP-independent Processing of Jaw1TM2[NP147] Is Not
Lymphoid Restricted. Because a homolog of mouse Jaw1 is
expressed endogenously by T2 cells, it was plausible that a
protein with Jaw1 receptor activity might participate in de-
livering Jaw1(TM2)[NP147] to the ER of T2 cells. We ex-
amined the presentation of Jaw1(TM2)[NP147] in HeLa
cells, which do not detectably express Jaw1 (27). To block
the  function of TAP, cells were coinfected with a rVV-
expressing  herpes simplex virus ICP47, a potent inhibitor of
human TAP function (41). Coexpression of ICP47
blocked presentation of VV determinants to polyclonal
VV-specific TCD81, and also full-length NP to NP147–155-
specific TCD81 (Fig. 7). By contrast, the presentation of
Jaw1(Lum2) [NP147–155] or Jaw1(TM2)[NP147–155] was un-
affected. This demonstrates that the TAP-independent
presentation of the two protein occurs in cells that do not
naturally express Jaw1.
Discussion
We recently found that the liberation of peptides from
the COOH terminus of Jaw1 is representative of a process
that occurs with both soluble and membrane-bound pro-
Figure 7. Tap-independent
presentation in nonlymphoid
cells. HeLa cells coinfected with
rVVs expressing Kd, a Jaw1 chi-
merical protein, and either
ICP47 or no foreign protein
were tested for recognition by
TCD81 populations specific for
NP or VV at the indicated effec-
tor to target ratio.1095 Snyder et al.
teins (Snyder, H.L., manuscript submitted for publication).
Based on these findings, we have proposed the C-end rule:
antigenic peptides are preferentially produced from the
COOH terminus of precursor peptides or proteins in the
ER. We believe that this reflects the normal NH2-terminal
trimming of TAP-transported extended peptides with the
proper COOH termini for class I binding.
Peptide liberation from the COOH terminus of Jaw oc-
curs much more efficiently than from the other full-length
substrates we have tested (an ER-targeted form of NP and
CD23). Of these proteins, only Jaw provided sufficient
quantities of peptide to detect enhanced expression of Kd in
T2 cells (Fig. 4; our unpublished findings). In the case of
Jaw1[NP147–155], the relatively high efficiency of peptide
liberation is presumably associated with the proteolytic
processing of its lumenal domain detectable biochemically.
The nature of the endoprotease acting on the lumenal do-
main of Jaw1 is unknown: we presume that an additional
aminopeptidase activity is required for final processing of
NP147–155. Endoprotease activity would appear to be limit-
ing inasmuch as peptide liberation was enhanced by coex-
pression of yeast Kex2.
Peptides were more efficiently liberated form Jaw1
(Lum2)[NP147–155] than from Jaw1[NP147–155]. Jaw1(Lum2)
[NP147–155] was produced to take advantage of a potential
signal peptidase cleavage site at the junction of the trans-
membrane and lumenal domains. The efficient liberation of
NP147–155 from Jaw1(Lum2)[NP147–155] is consistent with
the involvement of signal peptidase. Given the mechanism
of Jaw insertion into the ER, this would mean that signal
peptidase is operating posttranslationally. There is a prece-
dent for this in antigen processing studies. The limited
length of ER-targeted peptides dictates that they also must
be posttranslationally inserted into the ER (the leader se-
quence does not emerge from the ribosome before transla-
tion is completed), where it is assumed that signal peptidase
liberates the peptide from the leader. However, unlike
Jaw1, ER-targeted peptides probably enter the ER via the
translocon. The efficient processing of Jaw1 suggests that
signal peptidase can act on proteins that are inserted into
the membrane in a translocon-independent manner.
ER-targeted peptides have been shown to be more im-
munogenic than full-length proteins (42). This correlates
with their highly efficient loading of class I molecules; we
recently found that the NP147–155 determinant processed
from full-length VV-encoded NP is present at z30 copies/
cell while 55,000 copies are recovered from cells expressing
the ER-targeted peptide (36). The data in Fig. 6 suggest
that Jaw1 is equally or more adept at delivering peptides to
class I molecules than simple signal sequences. It will be of
interest to determine how Jaw1 compares with signal se-
quences in enhancing the immunogenicity of defined pep-
tides.
We unexpectedly found that a control Jaw1 construct
lacking a transmembrane region was presented in a TAP-
independent manner, albeit much less efficiently than ER-
targeted Jaw1. We provide immunocytochemical evidence
that the protein remains localized to the cytosol. Although
we cannot rule out that a minor fraction of the protein is
delivered to ER, examination of its sequence reveals no se-
quences of sufficient hydrophobicity to account for this ac-
tivity. Most curiously, presentation of NP147–155 from its
COOH terminus was dependent on a protease activity dis-
tinct from the proteasome in being unaffected by lactacys-
tin and blocked by cbz–LL–CHO. The same activity was
not required for TAP-independent presentation of the
NP147–155 peptide liberated from the COOH terminus of
other polypeptides directly targeted to the ER. This sug-
gests that the requisite protease is located in the cytosol.
The other major defined cytosolic proteases inhibited by
Z–LL–CHO, Z–LLL–CHO, and Z–LLF–CHO are the
calpains. However, these are unlikely to be required for the
presentation of Jaw1(TM2)[NP147–155], because two addi-
tional potent calpain inhibitors failed to affect presentation,
even at quite high concentrations. Thus, it appears that we
have uncovered a novel cytosolic protease that contributes
to antigen processing. Because all of our experiments have
used VV to express Jaw1(TM2)[NP147–155], it is possible
that the protease is a VV gene product. Similarly, it is possi-
ble that transport of the Jaw1(TM2)[NP147–155]–derived
peptide into the ER is dependent on an ongoing VV infec-
tion.
The putative cytosolic protease may be necessary to
maintain the ability of cells to transport the intact
Jaw1(TM2)[NP147–155] molecule to the ER. Alternatively,
the protease may be involved in producing a fragment from
Jaw1(TM2)[NP147–155] that is exported into the ER. This
fragment cannot be the naturally processed peptide, be-
cause this peptide, when expressed as a minigene product,
is not presented by T2 cells under the same conditions.
The mechanism by which the fragment gains access to the
ER appears to be related to the special properties of the cy-
tosolic domain of Jaw1, because neither NP147–155 nor
other peptides are presented in a TAP-independent manner
when appended to the COOH terminus of cytosolic NP
(Snyder, H.L., I. Ba ík, J.W. Yewdell, T.W. Behrens, and
J.R. Bennink, manuscript submitted for publication). Because
TAP-independent presentation of Jaw1(TM2)[NP147–155] is
observed in cells that do not express Jaw1, the mechanism
of transport is unlikely to be strictly related to the normal
function of Jaw1.
There are a number of examples of TAP-independent
peptide presentation that cannot be attributed with reason-
able certainty to translocon-mediated transport. RMA/S
cells, which lack the TAP2 subunit, are able to present
peptides from numerous cytosolic proteins, although at
much lower efficiency than parental RMA cells (43–47).
However, this has been claimed to result from TAP1 par-
tially functioning (48). By contrast, T2 cells do not detect-
ably present cytosolic antigens presented by RMA/S cells,
and human TAP1 has an absolute requirement for TAP2 to
transport peptides in T2 cells (13). T2 cells have been re-
ported to present cytosolic peptides produced from trans-
fected minigenes (21). In this case, the levels of direct pep-
tide production are enormous compared with the relatively
inefficient liberation of peptides from cytosolic proteins by
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